

1 **Antibody responses to SARS-CoV-2 vaccination in patients with acute leukaemia and high**
2 **risk MDS on active anti-cancer therapies**

3
4 **Chan, W.Y.¹, Zhu, C.^{1,2}, Sanchez, E.³, Gupta, R.^{1,2}, Fielding, A.K.^{1,2}, Khwaja, A.^{1,2}, Payne,**
5 **E.M.^{1,2*}, O’Nions, J.^{1*}**

6
7 **AFFILIATIONS:**¹Department of Haematology, University College London NHS Foundation Trust,
8 London, UK. ²UCL Cancer Institute, University College London, London, UK, ³Department of Virology,
9 University College London NHS Foundation Trust, London, UK. *Co-corresponding authors.

10
11 **Abstract**

12 Patients with haematological malignancies, such as acute leukaemia and high-risk MDS (HR-MDS),
13 have significantly increased mortality and morbidity from COVID-19. However vaccine efficacy in
14 these patients and the impact of systemic anti-cancer therapy (SACT) on vaccine response remains
15 to be fully established. SARS-CoV-2 antibody responses in 53 patients with ALL, AML or HR-MDS
16 receiving SACT were characterised following two doses of either BNT162b2 or ChAdOx1nCoV-19. All
17 patients were tested for anti-S antibodies after 2 doses, 60% after the first dose and anti-N antibody
18 testing was performed on 46 patients (87%). Seropositivity rates after 2 vaccine doses were 95% in
19 AML/HR-MDS patients and 79% in ALL. After stratification by prior SARS-CoV-2 infection, naïve
20 patients with AML/HR-MDS had higher seroconversion rates and median anti-S antibody titres
21 compared to ALL (median 291U/mL versus 5.06U/mL), and significant increases in anti-S titres with
22 consecutive vaccine doses, not seen in ALL. No difference was seen in serological response between
23 patients receiving intensive chemotherapy or non-intensive therapies (HMA) but significantly
24 lower titres were present in AML/HR-MDS patients who received non-toxic based regimens.

25 compared to other therapies. All ALL patients received intensive chemotherapy, with no further
26 impact of anti-CD20 immunotherapy on serological response. Understanding the impact of disease
27 subtypes and therapy on vaccine response is essential to enable decisions on modifying or delaying
28 treatment in the context of either SARS-CoV-2 infection or vaccination.

29

30 **Introduction**

31 SARS-CoV-2 vaccination represents an important measure to protect the population from COVID-19,
32 showing excellent rates of seroconversion and efficacy in preventing severe disease^{1,2}. However,
33 vaccine efficacy remains to be fully-established in patients with haematological malignancy who have
34 significantly increased mortality and morbidity from COVID-19^{3,4,5}. Variable humoral responses to
35 SARS-CoV-2 vaccination have been reported, with the lowest seroconversion rates in patients with B-
36 cell malignancies and those receiving systemic anti-cancer therapy (SACT)^{6,7,8,9}. Encouraging
37 seroconversion rates in patients with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia
38 (AML) and HR-MDS have been reported within larger cohort studies of patients with a variety of
39 haematological cancers^{7,10,11,12}. However, the impact of SACT on vaccine responses in patients with
40 ALL, AML and high-risk myelodysplastic syndrome (HR-MDS) remains unclear, but has important
41 implications for clinical management. Here we have addressed this and report SARS-CoV-2 antibody
42 responses following vaccination in patients with ALL, AML or HR-MDS receiving SACT .

43

44 **Methods**

45 Demographics, SACT history and laboratory parameters were collected from electronic health records
46 for patients with acute leukaemias and HR-MDS receiving or recently completed SACT, who had two
47 doses of SARS-CoV-2 vaccine (BNT162b2 or ChAdOx1nCoV-19) between December 2020 and July 2021
48 (with 8 to 12 weeks between doses as per UK vaccination programme). Serological testing was
49 performed using the Roche Elecsys anti-SARS-CoV-2 enzyme immunoassays. All patients were

50 consented for excess serum to be stored and used as part of the “UCL Biobank for Studying Health
51 and Disease, Haematology Project” (ref.NC10.13).

52

53 **Results**

54 Fifty three patients (62% AML, 11% HR-MDS, 26% ALL), underwent serological testing after receiving
55 2 vaccine doses (72% BNT162b2, 15% ChAdOx1nCoV-19, 13% unknown), Table 1. Median age was 53
56 (range 18-76) and all received or had recently completed SACT at time of vaccination; 21 patients
57 (39.6%) received intensive chemotherapy, 37.7% venetoclax-combination therapy (with azacitidine,
58 low-dose cytarabine or gilteritinib), 16.9% non-intensive (azacitidine) and 5.6% B-cell directed
59 immunotherapy (blinatumomab, CD19-CART). Forty-six (87%) underwent testing for anti-N
60 antibodies, identifying 11 (24%) showing previous SARS-CoV-2 infection. All patients were tested for
61 anti-S antibodies after 2 doses (median 43 days post-dose) and 60% after first dose (median 37.5 days).
62 A trend towards higher rates of seropositivity was seen in AML and HR-MDS compared to ALL after 2
63 doses (95% compared to 79%, $p=0.06$, Figure 1A). The seropositivity rate after dose one in all patients
64 was 75% (median anti-S titre 7.275U/ml [IQR 0.64-184]), rising to 91% following dose two (median
65 249U/ml [IQR 24.95-1721]), Figure 1B. There was no significant difference in anti-S seropositivity rate
66 or median antibody titre after dose one between patients with AML/HR-MDS and ALL (74% vs 78%
67 seropositive, median titres 5.90U/ml [IQR 0.58-56.70] versus 11.4U/ml [IQR 0.61-1380]). However,
68 patients with AML/HR-MDS showed significantly increased titres following dose two (median
69 333U/mL [IQR 86.60-1971], $p=0.0005$, 95% seropositive), compared to ALL (median titre 8.40 [IQR
70 2.34-669], $p=0.38$, 79% seropositive).

71 To define vaccine-induced seroconversion, we analysed responses in patients with no prior SARS-CoV-
72 2 infection and negative anti-N serology (Figure 1C, Figure S1A). Anti-S seroconversion was 91% with
73 median titre of 132U/mL (IQR 7.5-931). Seroconversion rates and median titres in SARS-CoV-2 naïve
74 patients remained higher in the myeloid compared to lymphoid cohort (median 235U/mL [IQR 82.15-

75 1670] versus 5.06U/mL [1.69-175.6], $p=0.0079$). A marked increase in titres was seen following
76 consecutive vaccinations in the AML/HR-MDS cohort (medians post dose one and two of 1.1U/mL and
77 95.8U/mL, $p=0.08$), but only minimal increase in ALL (0.817U/ml to 4.80U/mL, $p>0.99$) (Figures 1D, E,
78 F, Figures S1B, C). Previous SARS-CoV-2 infection was associated with higher antibody titres after two
79 vaccinations in patients with AML/HR-MDS (median 2500U/mL [IQR 141-2500]) compared to ALL
80 (median 1541U/mL [IQR 574.5-2500], although this did not reach significance ($p=0.77$) (Figure 1G,
81 Figures S1D,E). This is consistent with reports of higher overall post-vaccination antibody titres in
82 individuals with prior natural infection^{13,14}.

83 Next we investigated the impact of SACT type on serological responses. No significant difference in
84 seropositivity or antibody titres was seen in AML/HR-MDS patients receiving intensive (30% patients)
85 compared to non-intensive chemotherapy (azacitidine, 23%); however, anti-S titres were significantly
86 reduced in patients on venetoclax-based regimens (51% of myeloid patients, median 158.5U/mL [IQR
87 34.85-873], $p=0.04$). This was independent of previous SARS-CoV-2 infection (Figure 1H, Figure S2A).
88 The majority of ALL patients (79%) received intensive treatment (as per current UKALL protocols) and
89 had low anti-S titres post vaccination (Figure 1A,B,C,F). Anti-B cell directed therapy is associated with
90 poor serological response to SARS-CoV-2 vaccination. Five ALL patients received Rituximab but no
91 effect was seen on anti-S response, albeit in small numbers (Figure S2B,C).

92 Here we report the majority of patients with acute leukaemias and HR-MDS develop detectable anti-
93 S antibodies following two doses of SARS-CoV-2 vaccine, with seropositivity rates of 91%. SARS-CoV-
94 2 naïve patients with AML/HR-MDS showed significantly increased antibody responses following
95 consecutive vaccine doses, whereas ALL patients tended towards very low titres with a minimal
96 increase, and it remains to be established whether this is sufficient to confer protective immunity.
97 While patients with acute leukaemias can generate robust serological responses to natural infection,
98 this was not the case for all patients following vaccination, highlighting the importance of measuring
99 antibody titres, not just seropositivity, and to consider prior SARS-CoV-2 infection influencing vaccine

100 responses in this high-risk group. Understanding the impact of SACT on SARS-CoV-2 vaccine responses
101 is essential to guide decisions on treatment choice and timing. Reduced serological responses in
102 patients receiving B-cell directed therapy and small molecule inhibitors (particularly BTKi, venetoclax,
103 anti-CD20 and anti-CD19 immunotherapies) have been reported in mature B-cell neoplasms and
104 myeloma, but not acute leukaemias^{6,9,11,15}. While we found no significant difference in antibody titres
105 or seroconversion in AML/HR-MDS patients receiving intensive or non-intensive therapy, patients
106 receiving venetoclax-based regimens showed reduced antibody levels. Notably, ALL with intensive
107 chemotherapy displayed almost uniformly low antibody titres (<10U/ml) after two vaccine doses,
108 regardless of additional B-cell directed therapy. We propose that further work to define correlates of
109 vaccine protection (humoral and T cell responses), the impact of SACT regimens on the
110 magnitude/duration of responses, and the value of additional booster doses will have clear
111 implications for this vulnerable group and should be priority questions for larger prospective studies.

112

113 **Contributions**

114 JO conceived of the study, performed data collection, data analysis, literature search, and manuscript
115 writing and revision; WC data collection, data analysis, manuscript writing, and revision; CZ performed
116 data collection, manuscript review and revision; EP conceived of study, manuscript review and
117 revision; ES data collection, manuscript review and revision; AF, AK, RG, manuscript review and
118 revision.

119 **Declaration of interest:** All authors declare no conflicts of interest.

120 **Acknowledgements**

121 We are extremely grateful to all the patients who participated in this study and to the NHS staff that
122 provided their clinical care. EMP is supported by a CRUK Advanced Clinician Scientist Fellowship (Grant
123 No. A24873). RG acknowledges funding from Cure Cancer@ UCL.

124

125 **References**

126

- 127 1. Polack FP. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New*
128 *England Journal of Medicine* **383**: 2603–15 (2020)
- 129 2. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the
130 booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)
131 vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881–91 (2021)
- 132 3. Vijenthira A. *et al.* Outcomes of patients with hematologic malignancies and COVID-
133 19: a systematic review and meta-analysis of 3377 patients. *Blood* **136**:2881–92 (2020)
- 134 4. Wood WA. *et al.* Outcomes of patients with hematologic malignancies and COVID-19:
135 A report from the ASH Research Collaborative Data Hub. *Blood Advances* **4(23)**: 5966–
136 5975 (2020)
- 137 5. Passamonti, F. *et al.* Clinical characteristics and risk factors associated with COVID-19
138 severity in patients with haematological malignancies in Italy: a retrospective,
139 multicentre, cohort study. *Lancet Haematology* **7(10)**: e737–e745 (2020).
- 140 6. Addeo, A. *et al.* Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients
141 with cancer. *Cancer Cell* **39(8)**, 1091-1098 (2021)
- 142 7. Greenberger, LM. et al. Antibody response to SARS-CoV-2 vaccines in patients with
143 hematologic malignancies. *Cancer Cell* **39(8)**, 1031-1033 (2021)
- 144 8. Herishanu, Y. et al. Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in Patients with
145 Chronic Lymphocytic Leukemia. *Blood* **137**, 3165–3173 (2021).

- 146 9. Fox, TA. *et al.* Low seropositivity and suboptimal neutralisation rates in patients fully
147 vaccinated against COVID-19 with B-cell malignancies, *British Journal of*
148 *Haematology* **195(5)**, 706-709 (2021).
- 149 10. Malard, F. *et al.* Weak immunogenicity of SARS-CoV-2 vaccine in patients with
150 hematologic malignancies. *Blood Cancer Journal* **11**, 142 (2021)
- 151 11. Tzarfati, KH. *et al.* BNT162b2 COVID-19 Vaccine is significantly less effective in patients
152 with hematologic malignancies. *Am J Hematol* **96**, 1195–203 (2021)
- 153 12. Chung, DJ. *et al.* Disease- and Therapy-Specific Impact on Humoral Immune Responses
154 to COVID-19 Vaccination in Hematologic Malignancies. *Blood Cancer Discovery* **2(6)**,
155 568-576 (2021)
- 156 13. Anichini, G. *et al.* SARS-CoV-2 Antibody Response in Persons with Past Natural
157 Infection. *N Engl J Med* **385**, 90-92 (2021)
- 158 14. Predecki, M. *et al.* Effect of previous SARS-CoV-2 infection on humoral and T-cell
159 responses to single-dose BNT162b2 vaccine. *Lancet* **397(10280)**, 1178-1181 (2021)
- 160 15. Maneikis, K. *et al.* Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and
161 early clinical outcomes in patients with haematological malignancies in Lithuania: a
162 national prospective cohort study. *Lancet Haematol* **8(8)**, e583-e592 (2021)

163

164

165 **Figure legends**

166 **Figure 1:** Serological responses in patients with acute leukaemia and HR-MDS after SARS-CoV-2
167 vaccination. All figures are presented with a Log10 scale on the y-axis. A seropositive result is defined
168 as ≥ 0.8 U/mL, upper limit of the assay >2500 U/ml *lower limit of assay, **upper limit of assay. **1A:**
169 Seropositivity for anti-S antibodies in all patients following two doses of SARS-CoV-2 vaccine,

170 categorized by disease subtype. **1B:** Anti-S antibody titres following the first and second vaccine doses
171 by disease category. **1C:** Serological response to two vaccination doses in patients with no previous
172 SARS-CoV-2 infection. **1D:** Seroconversion rates in patients with no previous SARS-CoV-2 infection,
173 after one and two doses of vaccine (Paired pre dose, post first dose and second dose); in patients with
174 AML or HR-MDS (**1E**) and in patients with ALL (**1F**). **1G:** Serological response in patients with previous
175 SARS-CoV-2 infection categorized by disease subtypes. **1H:** Serological response following two doses
176 of vaccine in AML/HR-MDS treated with venetoclax-based regimens.

177

178

179

Table 1: Patient demographics, disease and treatment characteristics in the overall cohort and by disease subgroup.

Characteristics	Total n=53	Negative baseline n=35	Positive baseline n=11	Myeloid (AML + HR-MDS) n=39	Lymphoid n=14
Gender (% male)	30 (57)	18 (51)	6 (55)	21 (54)	9 (64)
Median age [range]	53 [18-76]	52 [18-76]	43 [22-73]	63 [21-76]	37 [18-57]
Diagnosis (%):					
AML/Myeloid Sarcoma	28 (53)	19 (54)	4 (36)	28 (72)	-
APML	5 (9)	3 (9)	2 (18)	5 (13)	-
HR MDS	6 (11)	4 (11)	1 (9)	6 (15)	-
B-ALL	10 (19)	7 (20)	3 (27)	-	10 (71)
T-ALL	4 (8)	2 (6)	1 (9)	-	4 (29)
SARS-CoV-2 infection*(%)	11/46 (24)	-	-	7/33 (21)	4/13 (31)
Treatment (% total patients):					
Intensive AML chemotherapy	10 (19)	7 (20)	3 (27)	10 (26)	-
Venetoclax based regimens	20 (38)	12 (34)	3 (27)	20 (51)	-
- Ven & Aza	16	10	2	16	-
- Ven & LDAC	2	1	0	2	-
- Ven & Gilt	1	1	0	1	-
- Ven, Gilt & Aza	1	0	1	1	-
Non intensive AML therapy	9 (17)	7 (20)	1 (10)	9 (23)	-
UKALL chemotherapy	11 (21)	9 (26)	2 (20)	-	11 (79)
- Plus Rituximab	5	3	2	-	5
Other B cell directed therapy	3 (6)	1 (3)	2 (20)	-	3 (21)
- Blinatumumab	2	1	1	-	2
- CAR-T	1	0	1	-	1
Seropositive**, 1 dose (%)	24/32 (75)	13/18 (72)	10/11 (91)	17/23 (74)	7/9 (78)
Seropositive**, 2 doses (%)	48/53 (91)	32/35 (91)	10/11 (91)	37/39 (95)	11/14 (79)
Seroconversion*** post 2 doses (%)	32/35 (91)	32/35 (91)	-	25/26 (96)	7/9 (78)
Vaccine type (%):					
BNT162b2	38 (72)	23 (66)	11 (100)	26 (67)	12 (86)
ChAdOx1 nCoV-19	8 (15)	6 (17)	0 (0)	8 (21)	0 (0)
unknown	7 (13)	6 (17)	0 (0)	5 (13)	2 (14)
Median time (days) from first dose to serology [range]	37.5 [24-86]	31 [24-79]	44 [24-79]	39 [24-79]	36 [26-86]
Time (days) from second dose to serology [range]	43 [13-133]	41 [13-133]	45 [15-72]	40 [13-133]	48 [15-84]
Median titres post first dose in all patients U/mL (IQR)	7.275 U/mL (0.64-184)	4.42 U/mL (0.4-17.10)	2500 U/mL (259-2500)	5.90 U/mL (0.58-56.70)	11.40 U/mL (0.61-1380)
Median titres post first dose in patients with negative baseline U/mL (IQR)	N/A	4.42 U/mL (0.4-17.10)	N/A	5.90 U/mL (0.62-38.35)	0.82 U/mL (0.4-9.64)
Median titres post second dose in all patients U/mL (IQR)	249 U/mL (24.95-1721)	132 U/mL (7.5-931)	2500 U/mL (417-2500)	333 U/mL (86.80-1971)	8.40 U/mL (2.34-669)
Median titres post second dose in patients with negative baseline U/mL (IQR)	N/A	132 U/mL (7.5-931)	N/A	235U/mL (82.15-1670)	5.06U/mL (1.69-175.6)

*SARS-CoV-2 infection defined by presence of anti-N (nucleocapsid) antibodies.

**SARS-CoV-2 seropositive defined by presence of anti-S (Spike) antibodies.

***Seroconversion defined by the detection of anti-S antibodies in patients who had previously undetectable anti-S antibodies.

Definitions: AML, acute myeloid leukaemia; HR-MDS, high risk MDS; B-ALL, B-lymphoblastic leukaemia; T-ALL, T lymphoblastic leukaemia; Ven, venetoclax; Aza, azacitidine; LDAC, low dose cytarabine; Gilt, gilteritinib; UKALL, (UK ALL chemotherapy 2011, 2014 protocols [anthracycline, vincristine, cytarabine, cyclophosphamide, peg-asparaginase, dexamethasone])

Figure 1: Serological responses in patients with acute leukaemia and HR-MDS after SARS-CoV-2 vaccination

